Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 8/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137726 | 1.00 | EGFR (0.53) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4137727 | 0.99 | EGFR (0.54) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4133902 | 0.93 | EGFR (0.54) | EGFRERBB2ALOX5HDAC4 | |
| SCHEMBL4133905 | 0.93 | EGFR (0.54) | EGFRERBB2ALOX5HDAC4 | |
| SCHEMBL4133908 | 0.92 | EGFR (0.55) | EGFRERBB2ALOX5HDAC4 | |
| SCHEMBL4122964 | 0.91 | EGFR (0.44) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4122968 | 0.91 | EGFR (0.44) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4122971 | 0.91 | EGFR (0.45) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4139742 | 0.91 | EGFR (0.45) | EGFRERBB2ALOX5HDAC4PPARG | |
| SCHEMBL4122900 | 0.85 | MAPT (0.49) | EGFRERBB2ALOX5HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | TORRENT PHARMACEUTICALS LIMITED (IN) | 2009-04-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088432-A1 | Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors | PTPRF, PTPA, PTPRJ | EGFR 729/4885ERBB2 138/4885ALOX5 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.